Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series

View More View Less
  • 1 Departments of Radiotherapy and Radiosurgery,
  • 2 Neurosurgery,
  • 3 Oncology and Hematology, and
  • 4 Neuroradiology, Humanitas Cancer Center and Research Hospital, Rozzano;
  • 5 Department of Biomedical Sciences, Humanitas University, Rozzano; and
  • 6 Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Italy
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Anaplastic gliomas (AGs) are an extremely heterogeneous group of primary brain tumors. More recently, new discoveries have indicated that isocitrate dehydrogenase (IDH) mutation status is the most important parameter predicting survival. The primary aim of the present analysis was to identify prognostic factors, other than IDH status, that eventually impact survival.

METHODS

Patients with available clinical, imaging, and molecular profile data who were amenable to resection were evaluated. The extent of resection (EOR) was defined as gross-total resection (GTR), near-total resection (NTR), subtotal resection (STR), or partial resection (PR). Residual tumor volume (RTV) was quantified. Following surgery, patients received adjuvant chemotherapy alone, radiation therapy plus concomitant and adjuvant temozolomide (TMZ), or sequential radio-chemotherapy. Clinical outcome was evaluated by neurological examination and MRI 1 month after treatment and every 4 months thereafter. Tumor progression was defined according to the Response Assessment in Neuro-Oncology (RANO) working group.

RESULTS

Among 402 patients referred to the authors’ institution for AG, 142 were included in the present analysis. Eighty-eight (62%) were male and 54 (38%) were female, with a median age of 43 years (range 19–70 years). At admission, most patients had a Karnofsky Performance Scale score of 90–100 (84.5%) and were symptomatic (93.7%). Forty-eight (33.8%) patients had newly diagnosed anaplastic oligodendrogliomas (AOs), and 94 (66.2%) had anaplastic astrocytomas (AAs). Most of them had mutant IDH tumors (67.6%) and methylated O6-methylguanine-DNA-methyltransferase (MGMT) promoter status (71.8%). GTR was performed in more than half of the patients (56.3%). RTV was detected in 83 (58.5%) patients. Following surgery, 72 (50.7%) patients received radiotherapy with concomitant and adjuvant TMZ, 48 (33.8%) received sequential radio-chemotherapy, and 22 (15.5%) received adjuvant chemotherapy alone. The median follow-up time was 40 months (range 16–146 months). The median PFS time and the 1-, 3-, and 5-year PFS rates were 35 months (95% CI 27–76) and 78.9% ± 3.4%, 49.7% ± 4.6%, and 42.7% ± 5.4%, respectively. The median OS time and the 1-, 3-, and 5-year OS rates were 91 months (95% CI 66–95) and 90.1% ± 2.5%, 70.9% ± 4.2%, and 61.8% ± 4.9%, respectively. Prognostic factors predicting survival other than molecular profile were the EOR and the RTV (p < 0.0001). Sequential radio-chemotherapy was the more effective treatment administered.

CONCLUSIONS

In addition to IDH status, EOR and the RTV have proved to statistically impact survival. The pivotal role of adjuvant radiotherapy has been recorded in all AG patients, regardless of tumor features.

ABBREVIATIONS AA = anaplastic astrocytoma; AG = anaplastic glioma; AO = anaplastic oligodendroglioma; AOA = anaplastic oligoastrocytoma; CE = contrast-enhanced; EOR = extent of resection; EORTC = European Organisation for Research and Treatment of Cancer; GBM = glioblastoma; GTR = gross-total resection; IDH = isocitrate dehydrogenase; KPS = Karnofsky Performance Scale; MGMT = O6-methylguanine-DNA-methyltransferase; NR = not reached; NTR = near-total resection; OS = overall survival; PCV = procarbazine, lomustine, and vincristine; PFS = progression-free survival; PR = partial resection; RTOG = Radiation Therapy Oncology Group; RTV = residual tumor volume; STR = subtotal resection; TMZ = temozolomide.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Federico Pessina: Humanitas Cancer Center and Research Hospital, Rozzano, Italy. federico.pessina@hunimed.eu.

INCLUDE WHEN CITING Published online September 4, 2020; DOI: 10.3171/2020.5.JNS201116.

Disclosures Dr. Santoro: consultant for Arqule and Sanofi; speakers bureau for Takeda, BMS, Roche, AbbVie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, and MSD; and advisory board for BMS, Servier, Gilead, Pfizer, Eisai, Bayer, and MSD.

  • 1

    Brat DJ, Verhaak RGW, Aldape KD, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):24812498.

    • Search Google Scholar
    • Export Citation
  • 2

    Brell M, Tortosa A, Verger E, Prognostic significance of O 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11(14):51675174.

    • Search Google Scholar
    • Export Citation
  • 3

    Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987996.

    • Search Google Scholar
    • Export Citation
  • 4

    Chahlavi A, Kanner A, Peereboom D, Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 2003;61(3):267273.

    • Search Google Scholar
    • Export Citation
  • 5

    Thiessen B, Maguire JA, McNeil K, Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 2003;64(3):271278.

    • Search Google Scholar
    • Export Citation
  • 6

    Levin VA, Silver P, Hannigan J, Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18(2):321324.

    • Search Google Scholar
    • Export Citation
  • 7

    Cairncross G, Berkey B, Shaw E, Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):27072714.

    • Search Google Scholar
    • Export Citation
  • 8

    van den Bent MJ, Carpentier AF, Brandes AA, Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):27152722.

    • Search Google Scholar
    • Export Citation
  • 9

    Wick W, Hartmann C, Engel C, NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):58745880.

    • Search Google Scholar
    • Export Citation
  • 10

    Wick W, Roth P, Hartmann C, Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016;18(11):15291537.

    • Search Google Scholar
    • Export Citation
  • 11

    Frenel JS, Leux C, Loussouarn D, Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neurooncol. 2013;114(1):8591.

    • Search Google Scholar
    • Export Citation
  • 12

    Olar A, Wani KM, Alfaro-Munoz KD, IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585596.

    • Search Google Scholar
    • Export Citation
  • 13

    Jiang H, Ren X, Cui X, 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol. 2013;15(6):775782.

    • Search Google Scholar
    • Export Citation
  • 14

    Louis DN, Perry A, Burger P, International Society of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429435.

    • Search Google Scholar
    • Export Citation
  • 15

    Wiestler B, Capper D, Sill M, Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561571.

    • Search Google Scholar
    • Export Citation
  • 16

    Suzuki H, Aoki K, Chiba K, Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458468.

  • 17

    Louis DN, Perry A, Reifenberger G, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803820.

    • Search Google Scholar
    • Export Citation
  • 18

    van den Bent MJ, Baumert B, Erridge SC, Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):16451653.

    • Search Google Scholar
    • Export Citation
  • 19

    Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753766.

  • 20

    Wen PY, Macdonald DR, Reardon DA, Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):19631972.

    • Search Google Scholar
    • Export Citation
  • 21

    Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1):113122.

    • Search Google Scholar
    • Export Citation
  • 22

    Grabowski MM, Recinos PF, Nowacki AS, Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):11151123.

    • Search Google Scholar
    • Export Citation
  • 23

    Stummer W, Reulen HJ, Meinel T, Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564576.

    • Search Google Scholar
    • Export Citation
  • 24

    Sanai N, Polley MY, McDermott MW, An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):38.

  • 25

    Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? J Neurosurg. 2016;124(4):977988.

    • Search Google Scholar
    • Export Citation
  • 26

    Yamaguchi S, Kobayashi H, Terasaka S, The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas. Jpn J Clin Oncol. 2012;42(4):270277.

    • Search Google Scholar
    • Export Citation
  • 27

    McGirt MJ, Chaichana KL, Gathinji M, Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156162.

    • Search Google Scholar
    • Export Citation
  • 28

    Pessina F, Navarria P, Cozzi L, Value of surgical resection in patients with newly diagnosed grade III glioma treated in a multimodal approach: surgery, chemotherapy and radiotherapy. Ann Surg Oncol. 2016;23(9):30403046.

    • Search Google Scholar
    • Export Citation
  • 29

    Beiko J, Suki D, Hess KR, IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014;16(1):8191.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 800 800 111
Full Text Views 102 102 22
PDF Downloads 73 73 21
EPUB Downloads 0 0 0